The North Carolina Translational and Clinical Sciences (NC TraCS) Institute wants you to be aware of a “Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)” released this week.
Notice of Special Interest: CTSA Program Applications to Address COVID-19 Public Heath Need – Earliest Submission date May 4
The North Carolina Translational and Clinical Sciences (NC TraCS) Institute wants you to be aware of a “Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need” released this week.
The NC TraCS Institute is pleased to announce awardees for $5K-50K matched pilot grants and $2K pilot grants related to the COVID-19 pandemic that were advanced for expedited review from the current cycle of proposals under review.
During this unprecedented time, we felt it was important to respond nimbly in funding pilot projects relevant to the current COVID-19 pandemic. To accomplish this goal we convened an ad hoc panel (Drs. Tim Carey, Janet Rubin, and Adaora Adimora) to review COVID-19 related $5K-$50K proposals 36 days ahead of schedule. For the $2K proposals, our regular review committee convened 10 days ahead of schedule.
In total, 5 applications were reviewed and 3 were chosen for funding. Awardees include investigators from UNC's Eshelman School of Pharmacy and School of Medicine. The $5K-$50K awards are comprised of NC TraCS funding matched by funds from UNC Schools, Departments and Centers, and funding from partner organizations. The 3 projects are listed alphabetically below by program and by the PI's last name.
As necessary, PCORI is adjusting the deadlines related to their funding announcements and quickly exploring ways that they can contribute to the evidence base for addressing this public health crisis.
PCORI is working to assist applicants and awardees in finding solutions that may help address issues related to disruptions associated with COVID-19, including general guidance and information about funding application deadline extensions.